PFM
RNAC icon

Privium Fund Management’s Cartesian Therapeutics RNAC Stock Holding History

Privium Fund Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Buy
179,114
+6,614
+4% +$47.1K 0.23% 42
2025
Q4 		$1.24M Buy
+172,500
New +$1.39M 0.23% 40

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Privium Fund Management's RNAC Position: Q1 2026 in Review

Privium Fund Management increased its Cartesian Therapeutics (RNAC) stake by 3.8% in Q1 2026, buying an estimated $47.1K and bringing the position to 179,114 shares worth $1.1M. The position accounts for 0.23% of the portfolio, ranked #42.

Privium Fund Management first reported a position in RNAC in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.24M in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Privium Fund Management held 179,114 shares of Cartesian Therapeutics worth $1.1M as of Q1 2026.
  • Privium Fund Management bought 6,614 Cartesian Therapeutics shares in Q1 2026, an estimated $47.1K.
  • Cartesian Therapeutics made up 0.23% of Privium Fund Management's portfolio in Q1 2026, its #42 holding.
  • Privium Fund Management first reported a position in Cartesian Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Privium Fund Management's Cartesian Therapeutics position peaked at $1.24M in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.